JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEUROCRINE BIOSCIENCES INC
Good afternoon, everyone. I really appreciate you joining us. My name is Akash Tiwari. I head our pharma and biotech research efforts internally within Jefferies, and I have the pleasure of hosting the Neurocrine management team. Very, very big 2027 catalyst slate for the company. You'd argue maybe the most important in the company's history. And so a lot to talk about the pipeline, and then also really the commercial portfolio as well. So I'm very much looking forward to it. Kyle, why don't I hand it off to you for some intro remarks, and we'll get started. That would be great. Thanks, Akash, and thanks to Jeffries for the invitation. It really is great to be here. Maybe just to start things off here, I'd like to also thank Jeffries for the following benefit of flying out here. For 10 hours, there was no Wi-Fi on our flight. I think those who know know the benefit of that. No email, no MS Teams, no text messages from the family. So it did give me a good opportunity to think, and I was thinking a lot about how much has changed at NERC over the past couple years when i stepped into the ceo role we were a single product company that was just ingresa of course we had a lot of ambition and that ambition continues to this day but fast forward to q3 we've got three first in class medicines an expanding portfolio and if you look at just our q3 performance we're annualizing now at about four and a half billion in sales i learned a lot along the way over the last couple years as well diversification is a wonderful thing when you're talking about the commercial portfolio or the R&D pipeline and we'll get some questions some Q&A on that I've also learned that when you have three medicines versus one you have a lot more to worry about and my family tells me that I perfected that part of the job over the past couple years but all jokes aside it's really been a pleasure working in this role and capacity at Neuroquin I'm pleased that the progress we've made over the past couple of years, starting with Ingresa and Q3, $800 million in sales. We had about 15% year-to-year growth, double-digit volume growth, record TRX, record NREX. We raised our guidance for the second time. It can go on and on, but it really does speak to the strength of the brand and our team and the hard work that we put into Ingres over the last couple of months. Over the past few years, Cronicity, our second year into the launch, we haven't completed the full second year but we're annualizing at a rate now about 850 million in sales of the 20,000 patients that are out there in congenital adrenal hyperplasia we have about 15 percent a little more than 15 percent under care of chronicity you really can see a line of sight for us changing the standard of care and then with vicat xr we've added another important medicine to our portfolio that we think has the potential to be a really long-term best-in-class medicine for patients with Prader-Willi syndrome, so we're looking to make good progress there in 2027. But what's even more exciting to see is that we're not just growing, the business is becoming stronger. We are becoming a much more diversified one. Approximately 30% of our revenue comes from medicines other than Ingresa. That would have been unheard of to think about just a few years ago. and then comes 2027. we have multiple phase two and phase three data readouts across our pipeline osa vampator and mdd will read out phase three studies uh direclidine and schizophrenia will also read out face three studies these are potential medicines that are trajectory changing for a company like neurogren i think related to that this year we have six new phase one starts five new phase two starts we've never been this productive from an r d perspective in all of our history so i think it paints a picture of a company that's evolving we're going to be having meaningful clean clinical data readouts as time moves along that will be the norm not the exception so when i look back at all the progress that we've made you know you really see a company that has a strong commercial foundation it has all the financial resources and a really rich and diverse pipeline that will drive growth well into the future so that literally is a flyby of the pipeline that came from sitting on the plane for 10 hours i'm sure we can dive in some of the details now but appreciate the opportunity before you do that two value-added comments sure first we are making forward-looking statements so check out our sec there you go and the second i guess value add is your team doesn't know that you're stressed so that's a good thing there you go. There we go. You know, and for the record, I never do work on flights. I'm sitting here watching rom-coms. But anyway, so let's get started. And I think over the last two years with Ingressa, there's been moving parts, right? There's a, oh, wow, maybe we kind of underinvested in certain areas, and there's a lot of moving parts. And there's been the big push with Teva. There's been the IRA. There has been the advent, if you can call it that, of Asito XR and what that's done from a pricing perspective. So there's been moving parts with the VMAT2 class, but it definitely, since talking to, you know, looking at Teva and their comments, but then also looking at your team, the error bars in terms of the commercial outlook for both products seems to have narrowed, and there seems to be increased visibility that maybe wasn't there in the last couple of years how much would you do those comments kind of resonate with you i know it's got you know you you talked about 27 pricing impact for ingress on the q3 call but what's underlying that also seems to be a really healthy uh confidence on volume uptake so do you feel like we've rebased in terms of the commercial trajectory and let us know as we go out to the end of the decade what's the kegger of this you know product um as it reaches maturity well maybe i'll start and then matt if you have some some comments and thoughts there i think um you know you touched on a couple different things there and maybe i'LL just share my general perspective and grez on the td market um it's amazing to think that nine years in we're still talking about a whole category that's growing uh in the mid-teens and that's exactly what we have here, and I think the underlying demand stems from the fact that TD itself, tardive dyskinesia, is a function of antipsychotic prescription volume and growth. That's the source and cause of TD, and that continues to grow at a clip of about 3% per year. There were 75 million prescriptions written last year, andthat's a multiple of the growth rate of the general population. So that's why you've seen us over the years have to update our prevalence numbers, because the denominator, the patient number, actually is increasing over time. So we've always felt like we've been trying to play catch-up here in the patients that are out there diagnosing them and then getting them under the care of Ingreza. It's led us to have a couple Salesforce expansions, so those are some of the things that we've learned over the years. But for the foreseeable future, antipsychotics aren't going away. We think we've got maybe a different type of approach to treat patients that have diseases of psychosis with our muscarinics, but those are a few years out. antipsychotics will continue to be a driving force for patients with these really debilitating diseases and conditions. So we have this underlying market that continues to grow. Greza fills that need there, and we think we've got a medicine that wins on clinical performance, ease of use, and even on price. And that's what's been winning the day in terms of payers and health care providers over time. Now, what I would say about the dynamics of the marketplace itself is that for the longest time, it's been a two-product category where companies contract with plans, as we've seen in other disease states and conditions. Next year, we move into a new era, if you will, where the two brands are working in different places when it comes to that area. We have our competitor in this space, Teva, that is going to be entering their first year of the IRA using their maximum fair price that will be pulled in overall, and they'll have great access. They'll have access to all the plans that they've been paying for over the past couple years. And Neurocrine with Ingresa, we will not be in an IRA moment. Ours happens in 2029. So it will be a different era, if you will, for a two-year period. And over this time frame, really what it comes down to still is access, and it's also share a voice. And for us in Neurocrime, I think moving into this year, the question was, what is our access going to be like in 27? Are we going to have to pay more for that access? And as time has moved along, we've addressed that piece. And what we would see moving forward is very similar access in 2027 and 28 as we have this year. So very strong access. Now, that comes with a bit of a price, net price per script, if you will. There's some concessions that we have to play for that. We also have a step-up in the statutory rebate that we pay for sales that go through Part D as a part of the Part D redesign in the IRA. But overall, that concession across those two metrics is going to be in the single to high or mid to single high digits, and that will be offset by the continued double-digit growth that we would expect on volume. So we'll be a net grower next year in terms of volume and a net grow next year in terms OF revenue. And we would see something similar like that for 28 as well. So overall, I think that's taken away a lot of the uncertainty, the airbars, if you will, as you said, for the next two-year period. And then 2029 is our IRA moment, and we will begin discussions, negotiations, if You Will, with CMS next spring, and that will conclude in the fall. Recall that we have the small biotech exemption that has a floor and a ceiling 25% to 34% off of a non-fam price. that will help guide us through negotiations. But overall, 2029 is going to be a very manageable year. We call it a divot, not a hole or a cliff that we'll be seeing in that year, and we'll able to then grow from that into the 2030s. So I think people are getting their hands around that, and that's very helpful for the business and allows us to focus on continuing investing in the brand and making it as big as it can be. Understood. Some very interesting comments there, particularly about IRA, Because, you know, it's funny, you talk to investors and they're like, oh, Neurocrine is saying, you know, 2029 and IRA, it almost sounds like, you know, the investor perception is the product goes X growth. That doesn't seem to be what you're saying. And so, and even when we do our own work and you net out the ostetoprice increases as patients switch to XR, it still also seems like the CMS was cognizant that this is a comorbid population, changes to access can have a meaningful downstream impact. And I feel like they were, let's say, pragmatic about what they were looking at from price concessions with an IRA perspective. So this has been a point of uncertainty. Can you expand a bit more on that? Is Ingresa going at growth post-2029? And really, how do we think about pricing impact that year? Yeah, the Austeto outcome, I think, is what you're alluding to was, I would say, for them, favorable outcome and I do think it reflects the value that it provides the patients as well as just understanding the dynamics of this patient population. So for us we do look at 2029 as being a manageable window of time. We know the error bars to your earlier comment. The price negotiation that we're going to have is indexed to a negative 25 percent to a 34 percent discount off of something called non-famp however you stop paying the statutory rebate which would have been eight percent at that time and you also are at a place where you're 100 on plans and covered so when you think about the net implications to price you can see yourself in a in a way to see that divot that kyle uh you know articulated and so we do see that 2029 window is definitely not falling off a patent event, this is something that's going to have sustained durable revenue growth coming out of 2029. Just saying that out loud, if I just think, I know you weren't discounting as much as Ostito was maybe two years ago, but that's been part of the discussion over the last couple of years is the gross net has improved as you try to get better access. In fact, I would probably guess you might be in the 25-ish percent range. I know you may not comment. But then if you think about the small biotech exemption and the range in terms of what the price discount is off WAC, and then the offset in termsof the penalty getting offset on CPI, I could see a scenario where when you say manageable, I say no price impact. Would you go that far and talk to us about some of the moving pieces? I'll say no. Don't agree that you'd go that far. However, it's not as extreme as what people would have anticipated. A few years ago, as you said, we were, if you said IRA, for whatever reason, you thought of Neurocrine, and that's because our largest product in Graza has 70% of Medicare Part is the mix of our underlying business. So I do think there's going to be a significant offset to that 25% to 34% decline. There are aspects, Akash, for example, that you have to think about best price for Medicaid and that fall into the Medicaid business as well. So there are aspects that you Have to more fully consider, but it is clearly more of a divot and then growing our cash flow significantly from there. So as Kyle said, two of the points of consideration that people have had for Ingresa or even for Nurikrin, how should you anticipate 27 and 28 when Osteto has an MFP? I think we've cleared that hurdle. We have strong access. We'd expect that access to be continued into 2028 and 2028 to be more of a low single-digit price decline year. And so with the underlying volumes that we're seeing in the double-digit range, we're going to be positioned to be a multi-blockbuster medicine for many years ahead with IP going out to 2038. And in addition to that, I'm sure we'll talk about it later, we do have a follow-on molecule that might lend itself to continue to expand and grow that market. Actually, just to hit on that, because it doesn't come up enough in discussions, when we look at LAIs, right? They ended up, I mean, first of all, really unmet need in the market because there was a comorbid population that really does struggle with adherence. It took 15% to 20% market share. I could argue that when we look at tardive dyskinesia, it's just as high of an unmet needs to actually get longer acting formulation. So what data are we going to get in 27 with the next-gen VMAT2s, and how quickly could we move to a long-acting paradigm? And then can you comment a bit about the unmet need that a long-acting therapy could provide based on your market research? Well, maybe I'll start, and then Irie can fill in some of the details here. But one of the things that I'm excited about the LAI technology and approach is that we hear from physicians when we have our ad boards, other discussions about Ingreza, that one ofthe unmet needs out there is a long acting injectable. And I think we've seen significant adoption of this type of approach for patients, in particular on the psychiatry side, over the past couple years with antipsychotics showing success there. We know that there are patients out there not getting Ingreza, an oral, once-daily medicine, because the physician is concerned that they won't stay on it once they leave their care. So having a long-acting injectable, I think, will open up a new side of the business that we haven't been able to tap into yet. So I think that's a really positive thing to think about when we look at our next-generation molecules that we're building and developing. I think the other piece of it is just it's a space in general that's not being satisfied out there, even amongst those patients that are taking our medicine today. So I Think there's multiple opportunities out there when we think about expanding the market. I don't think we'll get there with Ingreza, given the total daily dose that's attached to it. but our next-generation molecules were specifically designed to address this issue. And in terms of the data and timing, I'll let Irie talk about that. Yeah, so you're alluding to 890, which is our first of several next- generation VMAT2 inhibitors that we have, with two of those being in the clinic right now. The data from the Phase II dose-finding study for 890 read out in the middle of next year. I mean, and that molecule was designed to have the higher potency, so we're testing lower doses in that study than the 40 and 80 that we have for Ingresa. In addition, the molecule was chosen on other differentiating features of no 2D6 metabolism, also potentially a longer half-life in the context of that oral treatment, and moving away from the QT liability that's been associated with previous VMAT2 inhibitors. if as we read out the data next year those dosing information will inform the formulation work and the work on the lai then so what you'll see is us moving forward into phase three development registration development for the oral first and then in a somewhat staggered path we will be bringing forward the la i with the technology that most makes most sense because we have to have both the oral and the LAI available, which kind of gives one-stop shopping for a single molecule approach. Patients usually get stabilized on the oral first and then move to the LAIs for consistent follow-up therapy. I'll make this a dual-part question. A, as you improve half-life with your oral and then also LAI, is there a potential for improved efficacy with VMAT2? Is there a thesis there? And kind of lateral bridge, you have a next-gen chronicity, which will also have data next year. Is the improvement not just convenience, but is there potentially an efficacy improvement that could be had as you go to weekly? Speaking to the VMAT2 class, I mean, one of the things we know about this class of medicine, although we've seen adherence levels that have been significantly higher than the antipsychotics, we do know that compliance is still an issue with any oral therapy in there. And that does, given what we see with the rapid onset of activity of the VMAT2 inhibition in helping tardive dyskinesia, but rapid loss of efficacy if you take the drug away, then one could anticipate that you would see more consistent efficacy over a longer period of time with the LAI. Same could be true also for chronicity. What I will say, though, is that both those first medicines have set a high bar with respect to what we've seen in efficacy already. Right. And so, you know, I think that's an important feature. Understood. Calming a bit on chronicity. And, you know, it's one of these things where you have to disprove a negative, right? So Vertex will have their data, let's say, in the next year and a half. We'll see how quickly that trial rolls out. And I do think, like, the data's impressive. There's safety questions that will get answered with data. But there is, I thinking, an investor perception that, well, once Vertex goes on the market, I just don't know how to model Chronicity. And does Chronicety go, you know, like the revenue growth flatlines and we really have a mature product? That doesn't seem to be how your team talks about it. You alluded that Chronicty really could become standard of care. So as competition enters the market from Vertex, are you confident that you could still see continued growth in the Chronicy franchise? And do you think that an additional competitor maybe expands the market? Or do you think it actually will have an impact on your growth trajectory? Well, I think that always having multiple companies out there with products is going to help accelerate penetration of market, helping more patients. So you can't help but appreciate the benefits of that. I really like our approach that we have with chronicity. However, the way that we're tackling the disease is we're working upstream, trying to control the HPA access. That's the basic struggle the body has in CH. And the way that up until chronicity that patients, families with children with CH have tried to address it was by using super physiological doses of GCs, glucocorticoids. What chronicity allows them to do is capture, recapture the HPA axis for the first time, and it's the only approach in development, whether you're talking about chronicity or even our next generation medicine, that allows patients to reduce and control ACTH, which is a hormone that agonizes all melanocortin receptors on all tissues, not just on the adrenal gland, also helps reduce and normalize androgens, or A4, and it helps reduce excessive use of glucocorticoids. So it hits all facets of the disease. It's the only approach that does that. And ultimately, we think that will continue to drive the long-term data outcomes that we've seen with chronicity. Last year, we shared that endo two-year data in children and adults. This year will be three years of data and four years and so forth. We're always going to be in a leadership position to show the benefits of long- term treatment of our medicine, helping with ACTH, A4, and glucocorticoid dose reduction. And we think that's going to ultimately give us the opportunity to be a long-terms grower here overall in terms of penetrating the market of patients with CH as well as revenue. The last thing I would say with our long-term data is that we definitely have a significant advantage in terms OF pediatric data, in terms of an indication that takes patients or allows patients all the way down to four to start on treatment. And we have a study ongoing now that will allow us to treat patients all way down to just a few months old. And that's probably the right way to think about the disease, treating patients very early, very young. You can change the whole trajectory of their disease. And what we've seen play out commercially thus far is that the vast majority of patients have been on the children, the adolescent side of things. You can chance their growth trajectories. You can reduce their long-term exposure to glucocorticoids at a very young age. And the benefits of that will only compound over time. So I think we have a lot of things that we like. in our approach. I would say whether it's a competitor to Neurocrin or our next generation program, Kronesi is at a very high bar. Right. Understood. Going into the pipeline as we end the discussion, we hit on Osovampitor. You know, we're seeing, I think, an amazing transformation as psychedelics have really had, you know, you've seen several successful phase three studies and this kind of treatment resistant late stage depression um and i feel like there's always so much risk on mdd studies um but it does seem like giving you know a psychedelic it's it's potent but i think that's part of the story like yes there's no doubt it's a potent moa but there's an element of staying inpatient from phase two to phase three and controlling variables, whether it's site selection, making sure the studies aren't too large, which may apply not just to, you know, psychedelics, but really even apply to your program as well. Can you talk about the mistakes or the lessons you've learned in terms of MDD development in the field, and what is unique about the three phase three studies that you have reading out with OSA next year? Yeah, a couple of comments first. First, just one brief comment about psychedelics. I mean, I think, obviously, we have seen efficacy. At the end of the day, it's about benefit-risk, though, and also about how that medicine gets delivered and how it fits into the treatment paradigm. And I think that's still an area that's yet to be worked out. For Osovampator, just a few, that's an AMPA, positive allosteric modulator. And I think we have several reasons for confidence. And then I'll talk about the phase three program. The first is, obviously, this is a validated target. Actually, ketamine is part of what validates this target, working through glutamate to activate AMPA. We activate AMBA directly, so we avoid the glutamatergic surge and the psychotomimetic side effects that you see with a lot of these medicines, not just S-ketamine and ketamine. So when we look at our Phase II data, we also have a high level of confidence around the data that read out. We saw a large effect size of average placebo response and so confidence in moving forward with that dose. What we did in moving from phase two to phase three based on learnings from other programs was, first of all, we kept the program very, very simple. We know that things that drive placebo response in MDD trials are, first of All, the number of active arms, so the percentage of people who believe they are on active treatment and the investigator believes they're on active treatment. We kept that to 50-50. So that's the best kind of scenario to do that in. The second is the size of the trial. The larger the trial, because of more sites, because of more variability, the harder it is to get a positive outcome. And so our trial size in phase three is the same as our phase two trial size. 200 patients per trial. That's why we did three rather than two to give us an extra shot on goal there. The next thing is oversight of the investigative sites, and that starts from the very beginning with having as small a number of investigative sites as you can to minimize variability, appropriate oversight of training of those sites, ensuring that we're getting high-quality investigators who are trained appropriately to get high- quality patients into the study. And then the last piece in that oversight, just briefly I'll mention, is that the neuropsych division of the FDA encourages this input. Others do not. Other divisions do not, but we have an ongoing blinded data review of data as it's generated from individual site level and across the study. So as investigators start to enroll patients, we're looking at the curves that they're generating, both in terms of the nature of the screening for patients, but also the shape of the madras curves that are generated. And we have intervened and stopped sites, retrained sites, or given sites additional go-ahead on the basis of that quality. So that's pretty much what we're doing at an operational level. At the end of the day, obviously, the medicine has to perform, and these are higher risk areas in terms of but we're very excited about the prospect of reading out those trials in the second half of next year uh and just if i'll stick in one right now we're over but what can you comment about what you've seen on a blinded basis in terms of site conduct i know this is probably stuff samir's been running around yeah yeah those sites in florida team actually are running around at the site level and ensuring that quality i mean i think we're pleased in general i mean as it's a very very intensive activity what i can say as well just as we look at blind to data the other way we do that is looking at safety data on an ongoing basis we've had several data safety monitoring board reviews no changes in the program on the basis of that another thing that gives us confidence from a kind of tolerability safety point of view very low dropout rate from that program in phase three from the short-term studies and a very high, greater than 90% rollover into the open label extension, which again speaks well to the... You're already in open label expansion with some of your phasories. I'm sorry? You're all already in Open Label Extension. Oh, yeah. Yeah. I don't think that's what I said. On that note, I really appreciate it. It was a great conversation. Thanks so much, everyone. Thanks, Kosh.
- Company
- NEUROCRINE BIOSCIENCES INC
- Keywords
- NEUROCRINE BIOSCIENCES INC